Clinical Report: Analysis of Genetic Variants in CD16, CD32, CD40, and CD152

Overview

This systematic review and meta-analysis evaluated the associations of genetic polymorphisms in CD16, CD32, CD40, and CD152 with immune thrombocytopenia (ITP) using a comprehensive literature search and statistical analysis of effect sizes.

Background

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts due to increased destruction and decreased production of platelets. Understanding the genetic factors contributing to ITP can help clarify individual susceptibility.

Data Highlights

Key Findings

• The Fcb3RIIIA-158 F/V polymorphism is significantly associated with ITP susceptibility.
• The highest aggregated odds ratio for Fcb3RIIIA-158 F/V was 2.61 in the homozygous framework.
• No significant associations were found for Fcb3RIIA-131 H/R, Fcb3RIIB-232 I/T, CTLA-4 exon 1 A49G, CTLA-4 CT60, CD40 rs4810485 G > T, and CD40 rs1883832 C > T polymorphisms.
• Heterogeneity was highest for Fcb3RIIA-131 H/R in the heterozygous framework (I2 = 69%).
• The CD40 rs4810485 G > T polymorphism showed no heterogeneity across most frameworks (I2 = 0%).

Clinical Implications

The identification of the FcγRIIIA-158 F/V variant as a significant risk factor for ITP may guide future genetic screening and risk assessment in patients. Understanding these genetic associations can enhance the clinical management of ITP by informing treatment decisions.

Conclusion

The study indicates a significant association of the Fcb3RIIIA-158 F/V variant with ITP susceptibility, while other genetic variants did not show significant associations.

Related Resources & Content

1. American Society of Hematology 2019 guidelines for immune thrombocytopenia - PMC
2. FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia | FDA
3. Blood Cancer Journal — Prognostic and Therapeutic Insights from the Molecular Diversity of CD30+ Diffuse Large B-Cell Lymphoma
4. Blood Cancer Journal — Functional Assessment and Validation of GWAS-Identified Genetic Variants Linked to Chronic Lymphocytic Leukemia: Insights from the CRuCIAL Study
5. Blood Cancer Journal — Discovery of New STAT5B Mutations and Analysis of TCRβ Profiles in CD4+ T-Cell Large Granular Lymphocyte Leukemia
6. Blood Cancer Journal — Clonal Hematopoiesis Observed in Patients with Primary Immune Thrombocytopenia
7. American Society of Hematology 2019 guidelines for immune thrombocytopenia - PMC
8. https://itpaustralia.org.au/wp-content/uploads/2024/01/2024.01-ITP-Treatment-Guidelines_web.pdf
9. FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia | FDA
10. Frontiers | Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data
11. Association of FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms with various autoimmune diseases: a meta-analysis
12. Frontiers | The function of T cells in immune thrombocytopenia
13. Immune thrombocytopenia: a review of pathogenesis and current treatment | Discover Medicine | Springer Nature Link